Release of canine parvovirus from endocytic vesicles  by Suikkanen, Sanna et al.
Release of canine parvovirus from endocytic vesicles
Sanna Suikkanen, Mia Antila, Anne Jaatinen, Maija Vihinen-Ranta, and Matti Vuento*
Department of Biological and Environmental Science, P.O. Box 35, FIN-40014 University of Jyva¨skyla¨, Finland
Received 10 June 2003; returned to author for revision 11 July 2003; accepted 4 August 2003
Abstract
Canine parvovirus (CPV) is a small nonenveloped virus with a single-stranded DNA genome. CPV enters cells by clathrin-mediated
endocytosis and requires an acidic endosomal step for productive infection. Virion contains a potential nuclear localization signal as well
as a phospholipase A2 like domain in N-terminus of VP1. In this study we characterized the role of PLA2 activity on CPV entry process.
PLA2 activity of CPV capsids was triggered in vitro by heat or acidic pH. PLA2 inhibitors inhibited the viral proliferation suggesting that
PLA2 activity is needed for productive infection. The N-terminus of VP1 was exposed during the entry, suggesting that PLA2 activity might
have a role during endocytic entry. The presence of drugs modifying endocytosis (amiloride, bafilomycin A1, brefeldin A, and monensin)
caused viral proteins to remain in endosomal/lysosomal vesicles, even though the drugs were not able to inhibit the exposure of VP1
N-terminal end. These results indicate that the exposure of N-terminus of VP1 alone is not sufficient to allow CPV to proliferate. Some other
pH-dependent changes are needed for productive infection. In addition to blocking endocytic entry, amiloride was able to block some
postendocytic steps. The ability of CPV to permeabilize endosomal membranes was demonstrated by feeding cells with differently sized
rhodamine-conjugated dextrans together with the CPV in the presence or in the absence of amiloride, bafilomycin A1, brefeldin A, or
monensin. Dextran with a molecular weight of 3000 was released from vesicles after 8 h of infection, while dextran with a molecular weight
of 10,000 was mainly retained in vesicles. The results suggest that CPV infection does not cause disruption of endosomal vesicles. However,
the permeability of endosomal membranes apparently changes during CPV infection, probably due to the PLA2 activity of the virus. These
results suggest that parvoviral PLA2 activity is essential for productive infection and presumably utilized in membrane penetration process
of the virus, but CPV also needs other pH-dependent changes or factors to be released to the cytoplasm from endocytic vesicles.
© 2003 Elsevier Inc. All rights reserved.
Keywords: Parvovirus; Entry; Endocytosis; Phospholipase A2; Amiloride; Bafilomycin A1; Brefeldin A; Monensin; Membrane permeabilization; Transferrin
receptor
Introduction
The icosahedral, nonenveloped parvoviruses are among
the smallest of the animal viruses. The atomic structure of
canine parvovirus (CPV) capsid has been solved by X-ray
crystallography (Tsao et al., 1991; Xie and Chapman,
1996). CPV particle has a diameter of about 26 nm (Ag-
bandje et al., 1993). The capsid contains 60 protein subunits
of which 90% are VP2 (67 kDa) and 10% VP1 (83 kDa). In
full capsids containing DNA, some N-terminal ends of VP2
are exposed on the outside of the capsid and cleaved by host
cell proteases to form VP3 (65 kDa) (Paradiso et al., 1982;
Tattersall et al., 1977; Tullis et al., 1992; Weichert et al.,
1998). The cleavage exposes the conserved glysine-rich
sequence, which may be needed for interaction with cellular
membranes (Tattersall and Cotmore, 1988). VP1 contains
the complete amino acid sequence of VP2 in addition to a
143-residue unique N-teminal sequence that is buried within
the capsid (Paradiso, 1981; Weichert et al., 1998). VP1
N-terminal end can be exposed by treatment at high tem-
perature or with urea without complete disintegration of
capsid (Cotmore et al., 1999; Vihinen-Ranta et al., 2002;
Weichert et al., 1998). The canine parvovirus entry to the
host cell starts by binding to transferrin receptors, followed
by clathrin-mediated endocytosis and transport to the recy-
cling endosomes (Parker et al., 2001; Suikkanen et al.,
2002).
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Cytoplasmically microinjected antibodies to the trans-
ferrin receptor (TfR) cytoplasmic tail reduced CPV prolif-
eration when injected into cells 4 h after inoculation, show-
ing that many infecting capsids remain associated with the
TfR in endocytic compartments for several hours after up-
take (Parker et al., 2001). Before escape from endosomal
vesicles to the cytosol, CPV was detected in lysosomes
(Suikkanen et al., 2002). Antibodies to the CPV capsid
injected into the cytoplasm also prevented CPV prolifera-
tion when injected at 6 h postinfection, indicating that CPV
penetrates slowly out of the vesicles (Vihinen-Ranta et al.,
2002).
Cytoplasmic microinjection of antibodies recognizing
VP1 unique region inhibited the proliferation of CPV, in-
dicating that VP1 became exposed before nuclear entry of
CPV (Vihinen-Ranta et al., 2002). VP1 N-terminal end has
an essential role during the parvovirus entry. Virions with
their VP1 N-terminal unique sequence deleted were not able
to cause productive infection (Tullis et al., 1993; Vihinen-
Ranta et al., 2002). N-terminus of VP1 has been shown to
contain a potential nuclear localization signal in CPV and in
minute virus of mice (MVM) (Tullis et al., 1993; Vihinen-
Ranta et al., 1997). A phospholipase A2 (PLA2)-like domain
was found in the amino acid sequence of N-termini of VP1
of several parvoviruses (Za´dori et al., 2001). The role of
PLA2 activity of the VP1 unique region of most parvovi-
ruses has been demonstrated with inhibitors of PLA2, and
by mutations of the predicted active site, suggesting that the
viral PLA2 activity is needed at a step in the virus life cycle
between perinuclear accumulation and early gene expres-
sion (Dorsch et al., 2002; Girod et al., 2002; Li et al., 2001;
Za´dori et al., 2001).
Several viruses that enter cells by clathrin-mediated en-
docytosis undergo structural changes needed for productive
infection during endocytosis (Giranda et al., 1992; Kim et
al., 1990). Structural changes may be induced by binding to
the receptor with or without necessity for the virus to be-
come exposed to low pH (with; Miyazawa et al., 2001; Seth
et al., 1984a,b; Wickham et al., 1994; without: Greve et al.,
1991; Hoover-Litty and Greve, 1993). The receptor-medi-
ated endocytic uptake of picornaviruses and adenoviruses is
followed by penetration through endosomal membrane
(Marsh and Helenius, 1989). Poliovirus (a member of en-
teroviruses, a subfamily of picornaviruses) externalizes N-
termini of VP1 and myristoylated VP4 in the presence of
receptor both in vivo and in vitro, this leading to formation
of an altered virus particle, the A particle (De Sena and
Mandel, 1977; Gomez Yafal et al., 1993; Kaplan et al.,
1990). The formed A-particle has been shown to interact
with liposomes and to form ion channels in the membranes
(Fricks and Hogle, 1990; Tosteson and Chow, 1997). Sub-
group B adenoviruses (Ad7) have been shown to form
aggregates in the endocytic compartment (Chardonnet and
Dales, 1970; Dales and Chardonnet, 1973), and to cosedi-
ment and colocalize with lysosomal markers (Chardonnet
and Dales, 1970; Miyazawa et al., 2001; Ogier et al., 1977).
The optimal pH for lysis of endosomal membranes by Ad7
was shown to be 5.5, indicating that adenoviral disruption of
endosomes might be optimal in low pH compartments such
as late-endosomes or lysosomes (Miyazawa et al., 2001). In
addition to low pH conditions, adenovirus-mediated endo-
somal membrane permeabilization requires the interaction
of the virus proteins with the alphaV-integrin receptor (Seth
et al., 1984a,b, 1985; Wickham et al., 1994). The mecha-
nisms behind the membrane penetration process of CPV are
not well characterized. However, endosomal escape of CPV
particles did not allow release of coendocytosed alpha-
sarcin to the cytoplasm, indicating that viral penetration
through the endosomal membrane did not cause disruption
of endosomes (Parker and Parrish, 2000).
The aim of the present study was to clarify the role of the
VP1 N-terminal end and parvoviral phospholipase in CPV
entry process. Intracellular pathway of CPV was studied
using different inhibitors of endocytosis or phospholipase
A2 activity to gain further information about the viral escape
from endosomal vesicles and intracellular conditions en-
abling successful infection. The results of this article indi-
cated that parvoviral PLA2 activity found from the N-ter-
minal part of VP1 was triggered by treatments of acidic
buffers or heating. That sequence was exposed also during
the entry at 3–8 h p.i. in lysosomal vesicles, suggesting that
acidic pH of lysosomal interior triggers the activation of
viral PLA2. This further suggests that PLA activity might be
utilized in membrane penetration process. However, lyso-
somotropic drugs that inhibited viral proliferation did not
inhibit exposure of the N-terminus of VP1. This indicates
that PLA2 activity was not alone sufficient to allow CPV to
escape from endosomal vesicles. Some other pH-dependent
factors must also be needed for CPV to be released from
endocytic vesicles.
Results
Phospholipase A2 activity of CPV capsids
CPV capsids heated at least at 55°C or incubated at
acidic pH were tested for phospholipase A2 activity. The
results are shown in Figs. 1A and B. No activity was found
in nontreated full capsids or in capsids incubated at temper-
atures below 50°C. When capsids were heated up to 55°C,
they started to show PLA2 activity. PLA2 activity was also
tested after pretreatment at pH 4.0–7.0 with or without
neutralization step (Fig. 1A, without neutralization). CPV
capsids that were treated with buffers with pH 4–6 showed
PLA2 activity. Similar results were obtained when capsids
were neutralized after low pH treatment. The activity of
heated CPV capsids was abolished in the presence of 5 mM
EDTA and in the presence of quinacrine (QN) (2 mM; note
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that extra QN was removed by centrifugation before con-
ducting the assay due to the strong yellow color of this
reagent) or manoalide (MAN, 5 M), inhibitors of secreted
type PLA2 (Fig. 1B). PLA2 activity was also decreased by
pretreating heated capsids with polyclonal rabbit antibody
to CPV (RaVP1) antibody (2.5 mg/ml, Fig. 1B) compared
to anticapsid antibody (mouse monoclonal antibody to CPV
(MaCPV)) used at the same concentration. In contrast, in-
hibitor of cryptic phospholipase A2 arachidonyl trifluoro-
methyl ketone (AACOCF3) had no effect on PLA2 activity.
The effect of PLA2 inhibitors on CPV infectivity was tested
by inoculating cells with CPV capsids pretreated by heating
(2 min, 65°C) and by incubation with phospholipase A2
inhibitors for 2 h in RT (Fig. 1C). QN (0.2 mM) reduced
CPV infectivity from 74 to 13% and MAN (5 or 10 M)
treated capsids were completely devoid of infectivity. In-
stead, no decrease of infectivity was found when full cap-
sids were treated with of 0.2 mM AACOCF3. Higher con-
centrations could not be tested because of the toxic effects
exerted on cells by AACOCF3.
Exposure of VP1 N-terminus during entry
To determine the time frame of exposure of the N-
terminus of VP1 during entry, cells were inoculated with
full capsids, fixed at 1 to 8 h p.i., and analyzed by double-
labeling confocal immunofluorescence microscopy. For this
purpose we used RaCPV as a primary antibody to stain
capsids and MaVP1 to specifically detect VP1 proteins with
exposed N-terminus. Results from such an experiment are
shown in Fig. 2A. At 1 h post infection (p.i.) and later,
RaCPV showed a predominantly perinuclear staining pat-
tern (red color in Fig. 2A, 1 h p.i.). MaVP1 showed no
staining at 1 h p.i. (lack of green color and lack of yellow
color in merge-field Fig. 2A, 1 h p.i.). At 2–8 h p.i. MaVP1
antibody showed staining (green color in Fig. 2A) that was
perinuclear and merged with the red staining given by
RaCPV antibody. At 8 h p.i. the two perinuclear staining
patterns merged extensively, indicating that many virus
capsids showed exposed N-terminal ends of VP1 (Fig. 2A).
The antibiotic drug bafilomycin A1 (BFLA) has been
shown to inhibit proliferation of CPV and in the presence of
BFLA capsids were detected in endosomal vesicles (Parker
and Parrish, 2000). As BFLA and related drugs could be
expected to modify the intravesicular conditions by elevat-
ing the luminal pH, it was of interest to test whether they
could prevent the N-terminus of VP1 to become exposed.
The above experiment was repeated (Fig. 2B) in the pres-
ence of 0.4 mM amiloride (AMI), 500 nM BFLA, 20 nM
brefeldin A (BFA), or 500 nM monensin (MON). The
exposure of the N-terminal end of VP1 was detected as
colocalization (Fig. 2B, yellow color in merge field) be-
tween MaVP1 and RaCPV, despite the presence of any of
these drugs. All four drugs were able to significantly inhibit
the proliferation of CPV when they were added 2 h p.i. or
earlier (Fig. 3A). When added 0 h p.i., the drugs caused a
complete inhibition of proliferation. AMI and BFA still
caused a significant inhibition when they were added at 8 h
p.i., at which time the two other drugs no longer inhibited
viral proliferation. In fact, AMI was able to inhibit the
proliferation also when it was added as late as 16 h p.i. (Fig.
3A). A double-labeling immunofluorescence analysis of
cells at 20 h p.i in the presence of 0.4 mM AMI, 500 nM
BFLA, or 500 nM MON showed that CPV, when detected
with RaCPV as the primary antibody, was present mostly in
perinuclear vesicles that costained extensively with antibod-
ies to lysosomal membrane protein-2 (LAMP-2) used as a
marker for late endosomes and lysosomes, but not with
early endosomal marker (EEA1) (Figs. 3B and C). In the
Fig. 1. PLA2 activity of CPV capsid. (A) PLA2 activity of heat-treated or
low-pH-treated capsids. (B) PLA2 activity of heat-treated capsids incu-
bated (1 h) with PLA2-inhibitors (AACOCF3, QN, or MAN), EDTA,
RaVP1, or MaVP2. (C) Effect of PLA2 inhibitors on CPV proliferation.
For technical details, please see Materials and methods.
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presence of 20 nM BFA CPV was found to colocalize to a
certain extent with both antibodies to EEA1 and with
LAMP-2. Some confocal images (not shown) suggested that
CPV forms aggregates to the vesicular membrane. This
seemed to take place even in the presence of the above
drugs. The presence of aggregates was confirmed by immu-
noelectron microscopy (Fig. 4). In the presence of BFLA
and MON, gold labels indicating the presence of capsids
were found as clusters from the membranes of late-endoso-
mal and lysosomal resembling vesicles. In the presence of
AMI the gold label was again mainly found at the lysosomal
membrane, in addition to few cytoplasmic aggregates of the
label. The label on the cytoplasmic face was bound to CPV
capsids possibly caught in the process of penetrating
through the membrane. In controls with no drugs added,
some proportion of the label was found to be in the cyto-
plasm, while some label remained in contact with the lyso-
somal membrane. The results support the view that AMI,
BFLA, MON, and BFA inhibit the escape of CPV from
lysosomes. However, they did not prevent binding of CPV
to the lysosomal membrane.
Microinjections of CPV and infections with heat-treated
capsids in the presence of bafilomycin A1, monensin,
brefeldin A, and amiloride
To determine whether inhibition of CPV proliferation by
the above drugs could be due to some postendocytic step(s)
blocked by these drugs, low concentrations of nontreated
CPV was microinjected to cytoplasm of drug-treated NLFK
cells and localization of the capsids or appearance of NS1-
protein was studied with immunofluorescence microscopy
(not shown). Nuclear NS1 proteins and viruses (not shown)
were now observed in the presence of 500 nM BFLA, 500
nM MON, and 20 nM BFA, as well as in controls (no drugs
added), but not in the presence of 0.4 mM AMI (not shown).
The results confirm that the inhibitory action of BFLA,
Fig. 2. Double-labeling confocal immunofluorescence microscopy of CPV
endocytosed by NLFK cells. Exposure of N-terminus of VP1. Endocytosed
CPV was chased for the time indicated. (A) Left column, staining with
MaVP1 antibody (specific for the unique part of VP1 N-terminus, green
color) as the primary antibody. Right column, merged images with capsids
labeled with RaCPV (specific for CPV capsids, red color) and MaVP1
antibody (green). Colocalization, yellow color. (B) CPV chased for 16 h in
the presence of AMI (0.4 mM), BFLA (500 nM), BFA (20 nM) or MON
(500 nM). Merged images with capsids labeled with RaCPV (specific for
CPV capsids, red color) and MaVP1 antibody (green). Colocalization,
yellow color. Bars 10 m.
Fig. 3. Proliferation and endocytosis of CPV in the presence of lysosomo-
tropic drugs. (A) Endocytosed CPV was chased for 20 h in the presence of
500 nM bafilomycin A1, 500 nM monensin, 20 nM brefeldin A, or 0.4 mM
amiloride. Control, no drugs. Infected cells were labeled with antibody to
CPV capsids. Percentage of cells showing CPV proliferation (nuclear
fluorescence) at 20 h p.i. was determined. The drugs were added at the
indicated time points. (B) Labeling with antibody to CPV capsid (green
color) and antibody to EEA1 (red color); colocalization, yellow color. Bars
10m. (C) Labeling with antibody to CPV capsid (green color) and
antibody to LAMP-2 (red color); colocalization, yellow color. Bars 10 m.
Control (no drugs) was also labeled with antibody to CPV capsid (red
color) and antibody to LAMP-2 (green color).
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MON, and BFA (Fig. 3) was due to effects they exerted on
the endocytic route. In contrast, it appears that AMI inhib-
ited some steps in the entry route or proliferation of CPV
that occurred after release of CPV from the endosomal/
lysosomal vesicles.
To further elucidate the importance of VP1 N-terminus
in release of the virus from vesicles, cells were infected with
heat-treated (65°C) capsids showing PLA2 activity. Infec-
tivity was determined by immunofluorescence labeling of
NS1 or CPV capsid proteins after which percentage of cells
showing nuclear fluorescence was counted from 300 cells/
sample. Such capsids retained infectivity (Fig. 5), but the
infection was strongly inhibited by added drugs. Since the
drugs were able to inhibit proliferation of heat-treated CPV
having exposed N-terminus of VP1, it appears that exposure
of VP1 N-terminus was not the target of the inhibitory effect
of these drugs.
Colocalization of CPV with TfR during entry
The interaction of CPV with TfR was studied with LSM
by double labeling of infected cells fixed different time
points postinfection with two different monoclonal antibod-
ies to TfRs and with polyclonal antibody to CPV capsids.
CPV was found to colocalize with TfR for at least 10 h (Fig.
6A). Furthermore, TfR was found to colocalize in infected
cells with LAMP-2 at 8 h p.i. (Fig. 6B). At 1 h p.i. as well
as in noninfected cells only some colocalization was found
between TfRs and lysosomal vesicles.
CPV-induced release of dextran particles from lysosomal
structures
The electron micrographs of Fig. 4 may show CPV in the
process of penetrating the lysosomal membrane, but the
present resolution does not allow conclusions of mechanism
of penetration. To study further the mechanism of parvovi-
ral escape from endosomal vesicles, we coendocytosed
CPV with rhodamin-conjugated dextrans and chased for
2–20 h. In noninfected control cells, the rhodamine label of
the Mr 3000 dextran was found in vesicular-like structures
over the entire cytoplasmic cross section (Fig. 7A). A dou-
ble-labeling fluorescence/immunofluorescence analysis is
shown in Fig. 7B (dextran red, MaCPV-labeled CPV
green). According to fluorescence microscopy analysis, co-
endocytosed dextrans did not disturb CPV entry or prolif-
eration. In cells infected with CPV, dextran molecular sizeFig. 6. Double-labeling confocal immunofluorescence microscopy. (A)
Colocalization of endocytosed CPV with transferrin receptors. Endocy-
tosed CPV was chased for the time indicated. Staining with RaCPV
antibody (red color) as the primary antibody and with two different mono-
clonal antitransferrin receptor antibodies (green color). Colocalization,
yellow color. (B) Intracellular distribution of transferrin receptors and
LAMP-2. NLFK cells infected with CPV were fixed at 1 or 8 h p.i. as
indicated and immunolabeled with two different monoclonal antitransferrin
receptor antibodies (green color) and with Texas red conjugated LAMP-2.
Colocalization, yellow color. Areas marked with white squares are shown
in high magnification in the rightmost column (ZOOM).
Fig. 7. Release of dextran coendocytosed with CPV. (A) Dextrans endo-
cytosed by noninfected cells and chased for 20 h (B) Double-labeling
confocal immunofluorescence staining. CPV and rhodamine-labeled dex-
trans were coendocytosed by NLFK cells and chased for 20 h. On the left,
dextran with an M, of 3000 was used; on the right dextran had a Mr of
10,000. Red color, rhodamine; green color, CPV; yellow color, colocal-
ization. (C) Quantitative analysis of cells showing cytoplasmic and nuclear
dextran.
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Fig. 4. Immunoelectron microscopy of CPV endocytosed by NLFK cells in the presence of lysosomotropic drugs. Nanogold labeling with silver enhancement.
Endocytosed CPV was chased for 20 h in the presence of (A) AMI (0.4 mM), (B) BFLA (500 nM), (C) BFA (20 nM), or (D) MON (500 nM). (E) Control:
no drugs present. Nucleus (n), nuclear membrane (nm), lysosome (ly) are marked in the figure. Bars, 100 nm.
of 3000 was found in cytoplasm and in nucleus (red).
Release of dextran was detected also in cells, where CPV
was not yet detected in the nucleus. In contrast, the Mr
10,000 was retained exclusively in perinuclear vesicles both
in noninfected control cells (right frame in Fig. 7A) and in
infected cells (right frame in Fig. 7B). To quantify these
results, the percentage of cells showing released (cytoplas-
mical/nuclear) dextran was counted in the presence or ab-
sence of lysosomotropic drugs (Fig. 7C). In noninfected
control cells only few cells (1–3%) showed cytoplasmic or
nuclear dextran and no release of Mr 10,000 dextran was
detected in control cells or in infected cells even after 20 h
of infection. In contrast, Mr 3000 dextran was released to
cytoplasm in infected cells at 8 h p.i. and more cells show-
ing cytoplasmic and nuclear dextran were detected at 20 h
p.i. In infected cells treated with 0.4 mM AMI, 500 nM
BFLA, 20 nM BFA, or 500 nM MON the Mr 3000 dextran
was released to the cytoplasm, suggesting that these drugs
were not able to inhibit viral endosomal membrane perme-
abilization. In noninfected cells AMI, BFLA, BFA, or MON
caused no increase in the amount of cells showing released
dextran (not shown). The results suggest that CPV modified
late-endosomal/lysosomal membrane so that small-sized
dextrans (Mr 3000) could leak out, while larger dextrans (Mr
10 000) were mainly retained in the lysosomes.
CPV capsid interaction with lipids
Because membrane lipids are not randomly distributed
along endocytic pathways and their organelles (Simonsen et
al., 2001), it was of interest to study the lipid-binding proper-
ties of CPV. Clathrin-coated vesicles (CCVs) are enriched in
phosphatidylinositol 4- and 5-phosphates (PtdIns (4,5)P2) (Si-
monsen et al., 2001). Phosphatidylinositol-3-phosphates are
concentrated to early endosomal membranes, while lysophos-
phatidic acid and phosphatidylinositol-3,5-bisphosphate
(PtdIns (3,5)P2) are typical lipids for late endosomes (Koba-
yashi et al., 1998, 2002; Shisheva et al., 2001). In contrast,
sphingolipids and sulfatide are abundant in recycling endo-
somes (Gagescu et al., 2000; Ho¨ltta¨-Vuori et al., 2002). In this
study interactions of CPV capsids with lipids were studied with
arrays of phosphatidylinositols and sphingolipids (Molecular
Probes). CPV was found to bind to phosphatidylinositol-4-
phosphate (PtdIns(4)P), phosphatidylinositol-5-phosphate
(PtdIns(5)P), and phosphatidylinositol-3,5-bisphosphate
(PtdIns(3,5)P2). Some binding was detected also with
PtdIns(3)P, PtdIns(3,4)P, PtdIns(4,5)P, PtdIns(3,4,5)P, and
with phosphatidyl serine. These results suggest that CPV cap-
sids are able to bind to several membrane lipids found in the
membranes of many different endocytic organelles, including
at least clathrin-coated vesicles, early endosomes recycling
endosomes, and late endosomes. Five mM of EDTA abolished
CPV’s ability to bind to these lipids. Heated capsids and VP1
antibody-treated capsids had equal ability to bind to lipids as
untreated capsids, suggesting that VP1 N-terminus or its PLA2
domain is not responsible for lipid binding activity. Further-
more, CPV bound to sulfatide. Binding to sulfatide was not
inhibited by 5 mM EDTA.
Discussion
An interesting feature of the parvovirus capsid is the
capability of N-terminal unique sequence of VP1 to undergo
conformational changes. VP1 N-terminus is not accessible
in intact capsids but it is externalized in specific conditions
such as by heating or urea treatment, without complete
capsid disintegration (Cotmore et al., 1999; Vihinen-Ranta
et al., 2000; Weichert et al., 1998). Recently sequence
analysis revealed the presence of domains resembling
sPLA2 active sites in N-terminus of VP1 of diverse parvo-
viruses including CPV (Za´dori et al., 2001). In the present
study we show that PLA2 activity of CPV capsids was
triggered by heating the capsids (Fig. 1A). PLA2 activity
was not found in nontreated capsids or capsids heated at
50°C. Instead, capsids heated at 55°C or higher temperature
showed PLA2 activity. As N-terminus of VP1 has been
shown to be exposed by heating CPV capsids to 55°C by
Western blots (Vihinen-Ranta et al., 2002), it appears that
exposure of the N-terminus and activation of PLA2 are
interconnected. It follows that the PLA2 activity could be
used as a measure of exposure of the N-terminal unique
sequence. In addition, capsids treated with low pH (4–6)
buffer had PLA2 activity (Fig. 1B), suggesting that the low
pH of early endosomes or recycling endosomes is enough to
trigger PLA2 activity of CPV capsids during the endocytic
entry. Our results supported the earlier data indicating that
PLA2-like domain of N-terminal end of VP1 sequence acts
as secreted-type PLA2 (sPLA2) in parvoviral capsids as the
activity of the capsids was inhibited by antibodies against
N-terminal end of VP1, inhibitors of sPLA2 QN and MAN,
Fig. 5. Infectivity of heat-treated CPV in the presence of lysosomotropic
drugs. Cells were inoculated with heat-treated (65°C) CPV in the presence
of 500 nM BFLA, 500 nM MON, 20 nM BFA, or 0.4 mM AMI and fixed
at 20 h p.i. Control: no drugs present. Cells were immunolabeled with
MaCPV. Percentage of infected cells with fluorescent nuclei was counted
(n  300).
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or by 5 mM EDTA (Fig. 1B). Because this activity was
triggered by acidic pH that is found in endosomes, it was of
interest to test whether inhibitors of PLA2 could affect
endocytic entry of CPV. To study the role of PLA2 activity,
we treated capsids showing exposed VP1 N-terminals with
PLA2 inhibitors and used them for infections. MAN and
QN, which were able to inhibit viral sPLA2 activity, were
also able to reduce the amount of cells with productive
infection (Fig. 1C), indicating that viral PLA2 is essential
for the productive infection. This result is in line with earlier
results, where PLA2 activity of the VP1 unique region of
porcine parvovirus (PPV), human parvovirus B19, and ad-
enoassociated virus type 2 (AAV2) has been shown by
PLA2 inhibitor studies, and by mutations of the predicted
active site, proposing that the parvoviral PLA2 activity is
needed during some step(s) of viral life cycle between
perinuclear accumulation and early gene expression (Dor-
sch et al., 2002; Girod et al., 2002; Li et al., 2001; Za´dori et
al., 2001). We show here, by using antibodies specific to the
N-terminal part of VP1 together with anticapsid antibody,
that the VP1 N-terminal sequence became exposed during
the endocytic entry of CPV (Fig. 2A) at the time when CPV
had reached lysosomes. The lysosomal location of CPV at
this time point was also reported in earlier work (Suikkanen
et al., 2002). The results suggest that PLA2 activity can be
utilized for the membrane penetration by CPV when CPV
escapes from lysosomes. Our earlier results as well as
present results suggested that lysosomal vesicles are the
probable site of escape for CPV to the cytoplasm (Suik-
kanen et al., 2002).
Acidification is known to be an important factor for
successful parvovirus entry since drugs that change endo-
somal pH are able to block the infections (Bartlett et al.,
2000; Basak and Turner, 1992; Douar et al., 2001; Parker et
al., 2001; Ros et al., 2002; Vihinen-Ranta et al., 1998). In
the present study further information was collected about
the conditions that are needed for successful entry process
using four different drugs (AMI, BFA, BFLA, and MON)
modifying endocytosis. AMI is an inhibitor of Na/H
exchangers, which have been found at plasma membrane as
a part of the machinery that maintains the neutral pH of
cytosol (Noel and Pouyssegur, 1995; Yun et al., 1995). BFA
is thought to interfere with trafficking between early and
late endosomes and to have multiple effects on morphology
of endocytic organelles (Lippincott-Schwartz et al., 1991).
BFLA has been shown to cause inhibition of receptor–
ligand dissociation (Harada et al., 1997), inhibit endosomal
carrier vesicle formation (Clague et al., 1994) and late
endosome-lysosome fusion (Van Weert et al., 1995), as well
as cause fragmentation of early endosomes (D’arrigo et al.,
1997). MON, Na/H ionophore is known to raise pH of all
intracellular acidic compartments by exchanging of protons
for monovalent cations (reviewed in Pressman, 1976) and
thus, causing similar intracellular effects to those of BFLA.
Moreover, it has been shown that transferrin intake remains
intact in the presence of MON and BFLA (Johnson et al.,
1993; Stein and Sussman, 1986). In the present work, BFLA
and MON were able to block CPV infection (Fig. 3), being
in line with the earlier results indicating that parvoviral
entry is pH-dependent. In addition, we found BFA and AMI
to be potent inhibitors of CPV proliferation (Fig. 3). BFA
has been also found to inhibit MVM proliferation (Ros et
al., 2002). In the presence of BFA some capsids showed
colocalization with early endosomal as well as with lysoso-
mal markers, probably because the membranes of endocytic
machinery are somewhat mixed or the trafficking from early
endosomes is slowed down by BFA. Instead, in the presence
of the AMI, BFLA, or MON CPV capsids were found in
vesicles colocalizing with LAMP-2 to at least 20 h p.i. (Fig.
3C), while no colocalization was found with EEA1 in the
presence of those drugs even though the drugs were added
30 min before inoculation of the virus and cells were fixed
as late as 20 h p.i. (Fig. 3B). The result suggests that AMI,
BFLA, and MON do not inhibit the trafficking of CPV from
the early endosomes to the lysosomes. BFLA has been
shown to inhibit trafficking from the early endosome to late
endosome and to prevent fusion events between late endo-
somes and lysosomes (Clague et al., 1994; Van Weert et al.,
1995). As CPV that earlier had been shown to colocalize
with both recycling endosomal markers (Parker and Parrish,
2000; Suikkanen et al., 2002) and late endosomal/lysosomal
marker LAMP-2 (Suikkanen et al., 2002), the recent results
suggest that CPV does not need the route from early endo-
somes to late endosomes to enter to the lysosomes. Instead,
our results suggest that CPV may enter the cells via early
endosomes and perinuclear recycling route from which
CPV is delivered to the lysosomal vesicles.
When the endocytic pathway was bypassed by microinject-
ing CPV into the cytoplasm of the cells, AMI inhibited the
viral proliferation, but BFLA, MON, and BFA did not (not
shown). This suggests that AMI inhibited some step(s) taking
place after the endocytic phase in addition to its possible effect
on the endocytic phase, while BFLA, MON, and BFA affected
only the endocytic phase of CPV entry. Amiloride analogue
5-(N-ethyl-N-isopropyl)amiloride (EIPA) has been shown to
inhibit the escape of adenovirus type 2 from endosomes with-
out having any effect on viral uptake or on transferrin recycling
(Meier et al., 2002). In the same study Meier et al. found that
EIPA was also able to inhibit viral gene expression. This is in
line with our findings that AMI was able to inhibit CPV
infection even when added after CPV had already started its
replication (Fig. 3A). To clarify the role of exposure of VP1
N-terminus in entry process, we infected cells with heat-treated
CPV exposing VP1 N-termini in the presence of the drugs.
Heat-treated CPV caused infection such as nontreated CPV in
the absence of the drugs and infections of both heat-treated
CPV and nontreated CPV were inhibited in the presence of the
drugs (Figs. 3A and 5), indicating that the pH-induced expo-
sure of N-terminal end of VP1 is not sufficient for the release
of CPV from vesicles.
TfR is known to recycle back to the cell membrane in
noninfected cells (Mayor et al., 1993). It has been shown
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earlier by cytoplasmic microinjections of antibodies against
the TfR cytoplasmic tail that CPV-TfR interaction persists
for several hours. These microinjections inhibited CPV in-
fection when carried out at 4 h p.i. (Parker et al., 2001). We
found here that CPV capsids colocalize with TfR from the
beginning of the entry to 10 h p.i. (Fig. 6A), indicating that
the receptor is present while CPV is released to the cyto-
plasm. Furthermore, in CPV-infected cells more TfRs were
found from lysosomal vesicles at 8 h p.i. than at 1 h p.i. (Fig.
6B). The result may indicate that the presence of CPV
changed the routing of TfRs toward the lysosomes perhaps
by clustering the receptors (Marsh et al., 1995). This result
supports the idea presented above, that CPV enters the cells
via recycling route but is later rerouted to the degradative
pathway.
To be released to the cytoplasm, CPV must engage in
some kind of interaction with the vesicle membrane. Ag-
gregation of CPV to the lysosomal membrane was evident
from LSM images (not shown) and immuno-EM (Fig. 4).
Such an interaction was especially apparent in the presence
of the BFLA, MON, and BFA (Fig. 4) that did not allow
CPV to escape from the vesicles, and even in the presence
of AMI, which seemed to allow some viruses to escape (Fig.
4). The frame showing lysosomes in the presence of BFA is
especially interesting in that the label can be seen at a few
spots concentrated on both sides of the lysosomal mem-
brane (Fig. 4), possibly showing CPV in the process of
penetration through the membrane. Unfortunately, at the
present resolution of the electron micrographs, fine structure
of the membrane is not seen.
Viral escape from endosomes has been investigated by
cointernalization viruses or viral proteins with fluid-phase
markers such a dextran, calcein, carboxyfluorescein, and
horse radish peroxidase (HRP) (Prchla et al., 1995; Ruiz et
al., 1994; Suomalainen et al., 1999). Evidence for two
different mechanisms of escape used by adenoviruses or
human rhinovirus type 2 (HRV2) has been found by coin-
ternalization of differently sized dextrans with the viruses or
virus proteins. Adenovirus was found to be able to release
endosomal dextran almost size-independently, whereas re-
lease by HRV2 was shown to be highly size dependent
(Prchla et al., 1995). Escape mechanism of CPV has been
studied earlier by cointernalization of alpha-sarcin, where
no disruption of endosomes was found (Parker and Parrish,
2000). In the present study we cointernalized small dextrans
together with the virus to detect changes in membrane
permeability. When rhodamine-labeled dextrans (Mr 3000
or Mr 10,000) were coendocytosed with CPV, the Mr 3000
dextran was able to penetrate to the cytoplasm and migrate
further into the nucleus, while the Mr 10,000 dextran was
not able to escape from endosomal membranes in the ab-
sence or presence of the CPV (Fig. 7). Control experiments
showed that when endocytosed alone and chased for 20 h,
both dextrans remained in endocytic vesicles and did not
reach the nucleus (Fig. 7A). This indicates that CPV mod-
ified the permeability of the late-endosomal or lysosomal
membrane, allowing the smaller dextran to leak out (Fig.
7B), suggesting that dextran release caused by CPV is
highly size-dependent as shown earlier for HRV2 (Prchla et
al., 1995). These observations are in line with the results of
Parker et al., who showed that the endosomal membrane
retained -sarcin when coendocytosed with CPV (Parker
and Parrish, 2000).
Time schedule of viral membrane permeabilization and
the effect of the drugs (AMI, BFLA, BFA, or MON) on that
was assayed by determining the percentage of cells showing
released dextran in the cytosol and in the nucleus (Fig. 7C).
CPV-induced release of the Mr 3000 dextran was observed
at 8 h p.i. and later time points, while the viruses are being
released to cytoplasm as shown in our earlier studies (Suik-
kanen et al., 2002). In the present study none of studied
drugs was able to inhibit release of dextran despite the fact
that they arrested CPV in the lysosomal structures. This
suggests that membrane permeabilization, probably caused
by viral PLA2 activity, is not the only function needed for
release of CPV from vesicles. VP3, a proteolytic cleavage
product derived from VP2, contains conserved hydrophobic
polyglysine region at N-terminus (Bloom et al., 1988; Chen
et al., 1986 and reviewed in Cotmore and Tattersall, 1987)
and this polyglysine region has been suggested to be in-
serted into the membrane (Cortes et al., 1993). At present,
the role of VP3 is largely unknown and its role needs to be
investigated. Furthermore, it seems unlikely that CPV,
which is released to the cytoplasm in rather intact form
(Vihinen-Ranta et al., 2002), would be able to penetrate
through a pore of a size that would allow Mr 3000 dextran
but not Mr 10 000 dextran to pass through the membrane.
Thus, leakage may not necessarily indicate pore formation.
An argument against pore formation would also be that a
pore in the membrane would cause a rapid equilibration of
the pH gradient across the membrane. As discussed above,
there are reasons to believe that the maintaining of endoso-
mal acidic pH may be an important factor in the penetration.
Thus, the mechanism of the escape remains unsolved and
warrants further investigation.
It is known that enveloped viruses use fusion with plasma
membrane or with endosomal membranes to reach cytoplasm.
Membrane interactions of nonenveloped viruses are less well
understood. However, rhinovirus, poliovirus, and coxsackie
virus are known to be able to interact with lipid bilayers.
Furthermore, it has been shown that cell-surface nonsialyl
glycolipids might also play a critical role as receptors for
several viruses (Bhat et al., 1991; Brown et al., 1993). Re-
cently, lipids have been shown to contribute to the organization
and functions of the vacuolar system. Endosomes have been
shown to have a mosaic of structural and functional membrane
domains (Gruenberg, 2001). For example, CCVs are enriched
in phosphatidylinositol 4- and 5-phosphates, which seem to
have a key role of regulating CCVs (Jost et al., 1998). Phos-
phatidylinositol-3-phosphates which interact with proteins
containing a FYVE or a PX domain seem to be concentrated to
early endosomal membranes (Gillooly et al., 2000, 2001; Si-
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monsen and Stenmark, 2001 and reviewed by Simonsen et al.,
2001). Furthermore, lysophosphatidic acid and phosphatidyl-
inositol-3,5-bisphosphate (PtdIns(3,5)P2) are suggested to be
characteristic for late endosomes (Kobayashi et al., 1998,
2002; Shisheva et al., 2001), while sphingolipids are abundant
in recycling endosomes (Gagescu et al., 2000). In addition to
sphingolipids, sulfatides have been found to colocalize with
recycling endosomal markers such as Rab11 (Ho¨ltta¨-Vuori et
al., 2002). In present study we assayed CPV binding to sphin-
golipids and to phosphoinositides to investigate if CPV binds
to lipids and if the binding differs between studied membrane
lipids. Results showed that CPV was able to interact with
several phosphoinositides including PtdIns(4,5)P2 (generally
found in CCVs), PtdIns(3)P (usually concentrated to early
endosomal membranes), sulfatide (enriched in recycling endo-
somal membrane components), and PtdIns(3,5)P2 and lyso-
phosphatic acid found from late endosomal membranes, sug-
gesting that CPV might be able to interact the membranes of
these organelles also in vivo. Lipid binding seemed to be
Ca2-dependent as 5 mM EDTA reduced CPV’s ability to
bind to studied lipids (excluding sulfatide). Surprisingly,
heated capsids showing exposed VP1 N-terminae and VP1
antibody-treated capsids had equal ability to bind to lipids as
nontreated capsids, suggesting that VP1 is not responsible for
membrane binding. This further suggests that lipid binding and
PLA2 activity of CPV capsids are independent activities asso-
ciated with the capsids. A possible role of these lipids as
coreceptors needed for membrane penetration warrants further
investigation.
Several arguments speak in favor of PLA2 activity being
involved in the entry, as follows: (1) the PLA2 activity has
been located in the N-terminal part of VP1, (2) this part was
exposed at 3–8 h p.i. when CPV has reached lysosomes, (3)
the lysosomal interior is known to be acidic, and (4) the
PLA2 activity was activated by incubation of CPV at an
acidic pH. An interesting possibility is that the PLA2 activ-
ity of CPV capsids is responsible for the observed modifi-
cation of membrane permeability. (5) PLA2 inhibitors in-
hibited CPV entry, indicating that PLA2 activity is essential
for the successful infection. The exposure of VP1 was not
sufficient to allow CPV to penetrate to the cytoplasm in the
presence of lysosomotropic drugs, suggesting that there
might be some other factors (perhaps VP3 or receptor(s))




Norden Laboratories feline kidney (NLFK) cells were
grown and maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal calf serum
(Gibco, Paisley, UK). Canine parvovirus type 2 (CPV-d)
was derived from a plasmid clone of virus, as previously
described (Parker et al., 2001), and was grown in NLFK
cells in 175-cm2 cell-culture flasks (Nunc, Roskilde, Den-
mark) for 5 to 7 days and then stored at 20°C. Then, 300
ml of thawed culture medium was centrifuged at 3000g for
30 min and concentrated by ultrafiltration with 500-kDa
filter (Amicon ultrafiltrator). Viruses were pelleted with
ultracentrifugation at 173,000g for 2 h and resuspended in
900 l of phosphate-buffered saline (pH 7.4) (PBS). The
suspension was sonicated at low power and extracted with
chloroform. Then full and empty capsids were separated
from the aqueous phase of chloroform extraction by isopy-
cnic centrifugation in 45% cesium chloride gradient; opal-
escent bands were collected with a syringe and capsids were
pelleted by ultracentrifugation at 245,000g for 2 h. The
pellets were resuspended in 100 l PBS.
Assay of virus proliferation
To determine CPV proliferation, infected cells were in-
cubated for 20 h, after which the number of fluorescent
nuclei was determined with immunofluorescence micros-
copy. The primary antibody was MaCPV or MaNS1 (see
below). Proliferation was quantified as the ratio of cells with
fluorescent nuclei to the total number of cells, n  300.
Antibodies
RaVP1 to synthetic peptide representing a part of the
unique region of VP1 originated from the laboratory of prof.
P. Tattersall and S. Cotmore (Yale University, New Haven,
CT). This antibody has been shown not to react with VP2
and to react with CPV capsids only after the N-termimus
VP1 has become exposed (Cotmore et al., 1997). Mouse
monoclonal antibody to CPV (Mab8) (Strassheim et al.,
1994; Wikoff et al., 1994) and to N-terminal unique se-
quence of VP1 (MaVP1) and to nonstructural protein-1
(MaNS1) as well as RaCPV were from Prof. Parrish (Co-
mell University, Ithaca, NY). Monoclonal antibodies to
EEA1 and to cation-indepenent mannose-6-phosphate re-
ceptor (Ci-MPR) were generous gifts from Varpu Marjo-
ma¨ki (Juuti-Uusitalo et al., 2000). Monoclonal antibody to
LAMP-2 was from Developmental Studies Hybridoma
Bank (University of Iowa, Iowa City, IA). Monoclonal
antibodies to transferrin receptor were from Dako (Carpin-
teria, CA) and Molecular Probes. Alexa 546 and 488 con-
jugated goat anti-mouse and goat anti-rabbit antibodies
were from Molecular Probes. Nanogold-conjugated anti-
rabbit or anti-mouse IgG were from Nanoprobes (Yaphank,
NY). Alkaline phosphatase conjugated swine anti-mouse
antibody was from Dako.
Chemicals
Bafilomycin A1, monensin, brefeldin A, quinacrine, AA-
COCF3, and amiloride (N-amidino-3,5-diamino-6-chloro-
pyrazinecarboxamide) were from Sigma. Manoalide was
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from BioMol (Hamburg, Germany). Dextrans (Mr 3000 or
10,000) labeled with rhodamine were purchased from Mo-
lecular Probes. All other chemicals were from Merck (Ger-
many) and were of highest grade available.
Treatment of capsids with elevated temperature and with
PLA2 inhibitors
Purified heavy capsids of CPV (0.3–0.7 mg/ml in PBS)
were incubated for 2 min on heat block thermostated at
37–75°C (2°C), after which the samples were cooled
gradually to room temperature. To introduce PLA2 inhibi-
tors to the heated capsids manifesting PLA2 activity, capsids
were incubated with manoalide (5–10 M), quinacrine
(0.02–2 mM), or AACOCF3 (0.02–10 mM) for 1 h at room
temperature with agitation. Unbound quinacrine was re-
moved by pelleting CPV capsids by ultracentrifugation at
245,000 g for 2 h. The pellets were resuspended in original
volume of PBS. Antibodies (2.5 mg/ml) to VP1-terminal
end (RaVP1) or to VP2 (MaCPV) were incubated with
purified and heated (2 min, 65°C) capsids (0.5 mg/ml) for
1 h in room temperature with agitation. Heat-treated cap-
sids, capsids both heated and PLA2-inhibitor treated, as well
as capsids both heated antibody treated were used for PLA2
activity assay.
Treatment of capsids with acidic buffers
Samples of CPV dissolved in 0.9% NaCl were diluted in
0.1 M citrate buffer pH 4.0, 5.0, 6.0, or 7.0 and incubated
for 5 min at room temperature, and half of the samples was
brought to neutrality by adding predetermined aliquots of 1
M Tris base. The other half of the samples was used im-
mediately for PLA2 activity assay without neutralization.
Assay of phospholipase A2 activity
A commercial kit obtained from Cayman Chemical (MI,
USA) was used to assay for phospholipase A2 activity of
CPV capsids in vitro according to the instructions provided
by the manufacturer. The assay uses the 1,2-dithio analog of
diheptanoyl phosphatidylcholine, which serves as a sub-
strate for most PLA2s (Hendrickson et al., 1983). Upon
hydrolysis of the thioester bond at the sn-2 position by
PLA2, free thiols were detected by using DTNB (5,5-
dithio-bis-(2-nitrobenzoic acid)); 3–6 g CPV capsids were
used for these measurements. To control the effect of the
low pH buffer on the assay system, we used buffer pH 4 as
a sample. No unspecific signal caused by low pH was
detected.
Immunofluorescence microscopy
For immunofluorescense studies 80% confluent cells
grown on coverslips (diameter 13 mm) were inoculated with
DNA containing particles of CPV (m.o.i. 40–50). To study
the effects of endocytosis-modulating drugs, 0.4 mM AMI,
500 nM BFLA, 20 nM BFA, or 500 nM MON was added to
the cells 30 min before inoculation of the virus and the
drugs were maintained until fixation. After different times
postinfection coverslips were rinsed with PBS and fixed
with 4% paraformaldehyde (PFA) in PBS. After being in-
cubated with permeabilization buffer (containing 1% bovine
serum albumin (BSA), 1% Triton X-100, and 0.01% sodium
azide in PBS) for 15 min, the coverslips were incubated
with primary antibodies diluted with permeabilization
buffer for 45 min at room temperature and rinsed several
times with permeabilization buffer before incubation with
secondary antibody (45 min at room temperature). Cover-
slips were finally rinsed several times with permeabilization
buffer and embedded with mowiol-DABCO (30 mg/ml).
Confocal microscopy was conducted on a Zeiss LSM 510
inverted microscope (equipped with Nomarski DIC).
Preembedding labeling for immunoelectron microscopy
Cells were grown on 35-mm plastic culture dishes to
80% confluency. The cells were incubated with CPV (m.o.i.
50) in DMEM for 20 h in the presence or absence of AMI,
BFLA, BFA, or MON. Drugs were added on the top of the
cells 30 min before virus and maintained until fixation.
After 1–20 h dishes were washed with 0.1 M phosphate
buffer, pH 7.4 and the cells were fixed with PLP for 2 h at
RT (Brown and Farquhar, 1989). After rinsing with sodium
phosphate buffer, cells were permeabilized for 8 min at RT
with phosphate buffer containing 0.01% saponin and 0.1%
BSA or with 0.05% Triton X-100 in 0.1 M phosphate buffer
if the target was to visualize nuclear antigens. Primary
antibody (MaCPV or RaVP1) and gold-conjugated second-
ary antibody were diluted in permeabilization buffer and
incubated on the top of the cells for 1 h at RT. Between and
after labelings, cells were washed with permeabilization
buffer. Cells were postfixed with with 1% glutaraldehyde in
0.1 M phosphate buffer for 10 min at RT, quenched with 50
mM NH4Cl in phosphate buffer, and washed with both
phosphate buffer and water. Cells were treated in the dark
with HQ-silver (Nanoprobes) for 2 min, followed by washes
with water and gold toning solutions (2% sodium acetate 3
 5 min, 0.05% gold chloride 10 min on ice, 0.3% sodium
thiosulphate 2  10 min on ice). After washes with water,
the cells were postfixed with 1% osmium tetroxide in 0.1 M
phosphate buffer for 1 h at 4°C, dehydrated with a descend-
ing concentration series of ethanol, and stained with 2%
uranyl acetate. Plastic capsules filled with Epon LX-112
(Ladd Research Industries, Williston, VT) were placed up-
side-down on top of the cells. After polymerization, the
capsules were warmed up to 100°C and removed carefully,
and horizontal sections were cut with an ultramicrotome
(Ultracut 8008, Reichert-Jung) set to 50 nm, picked up on a
grid, stained with 2% uranyl acetate and lead citrate, and
viewed with an electron microscope JEM-1200EX (Jeol,
Japan).
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Microinjection of the CPV capsids
Capillary microinjection into NLFK cells was performed
using the transjector 5246 and the micromanipulator 5171
(Eppendorf, Hamburg, Germany) connected to an inverted
IMT-2 microscope (Olympus Optical Co., Tokyo, Japan).
Needles were pulled from glass capillaries (diameter 1.2
mm, Clark Electromedical Instruments, Reading, UK) using
a P-97 needle puller (Sutter Instruments, Novato, CA). For
the microinjection experiments, cells were grown to 80%
confluency on microgrid size coverslips (175-nm grid size;
Eppendorf). Cells were injected into cytoplasm with 0.1 to
0.5 pl of viral capsids at 0.5 to 1 mg/ml in PBS. For details
of drug treatments, immunolabeling, and imaging (please
see Immunofluorescence microscopy).
Release of dextran particles from endosomal vesicles
Cells were grown on coverslips (diameter 13 mm) to
80% confluency. The cells were pulsed with rhodamine-
conjugated lysine-fixable dextran (Mr 3000 or 10,000, 3
mg/ml) and H-CPV for 15 min in the presence or absence of
0.4 mM AMI, 500 nM BFLA, 20 nM BFA, or 500 nM
MON, after which they were chased for 2, 8, or 16 h in the
presence or absence of 0.4 mM AMI, 500 nM BFLA, 20 nM
BFA, or 500 nM MON. Controls were made without the
virus. Cells were fixed with 4% PFA and imaging was made
with Leitz DM RBE fluorescence microscope (Leica, Wet-
zlar, Germany) equipped with Spot CCD camera and Spot
RT software (Diagnostic Instruments Inc., Sterling Heights,
MI). Percentage of cells showing cytoplasmic and/or nu-
clear fluorescence was calculated (approximately 1500
cells/sample). The presence of the CPV was tested every
time by indirect immunofluorescence labeling as described
above. Immunofluorescence labeling of the viral capsids
was carried out as described above. In addition, anti-
LAMP-2 antibody was used to show late endosomal/lyso-
somal localization of the dextrans and viruses.
Assay of binding of CPV to lipids
To study lipid binding of CPV capsids, we used lipid-
containing membranes (PIP-strips and sphingo-strips) pur-
chased from Molecular Probes. Membranes were first
blocked overnight at 4°C with 3% fatty acid free bovine
serum albumin in Tris-buffered saline (TBS, pH 7.4). Then
membranes were incubated two times o/n at 4°C in TBS–
Tween (0.1%) containing 3% fatty acid free BSA and 1
g/ml purified CPV capsids. The membranes were then
washed with TBS–Tween several times. Bound viruses
were detected using capsid antibody (MaCPV) and alkaline
phosphatase conjugated secondary antibody, after which
substrate was introduced for 5 min and reaction was
stopped.
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